IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events
IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, has announced its participation in three major investor events in September 2025. The company will participate in a fireside chat at the Cantor Global Healthcare Conference on September 3rd, host its 10-Year Anniversary R&D Day on September 8th featuring clinical data updates and KOL Dr. Arun D. Singh, and attend the Morgan Stanley Global Healthcare Conference on September 9th for one-on-one meetings.
The R&D Day will showcase multiple clinical data updates, outline future catalysts, and review long-term portfolio strategy. Live audio webcasts will be available on the company's investor relations website, with replays accessible for 30 days post-event.
IDEAYA Biosciences (NASDAQ: IDYA), azienda di medicina di precisione in oncologia, ha annunciato la partecipazione a tre importanti eventi per investitori a settembre 2025. La società sarà presente a un fireside chat al Cantor Global Healthcare Conference il 3 settembre, organizzerà il 10-Year Anniversary R&D Day l'8 settembre con aggiornamenti sui dati clinici e l'intervento del KOL Dr. Arun D. Singh, e parteciperà al Morgan Stanley Global Healthcare Conference il 9 settembre per incontri one-on-one.
Il R&D Day presenterà diversi aggiornamenti sui dati clinici, illustrerà i prossimi catalizzatori e analizzerà la strategia di portafoglio a lungo termine. Saranno disponibili webcast audio in diretta sul sito investor relations della società, con le registrazioni accessibili per 30 giorni dopo l'evento.
IDEAYA Biosciences (NASDAQ: IDYA), compañía de medicina de precisión en oncología, ha anunciado su participación en tres importantes eventos para inversores en septiembre de 2025. La empresa participará en un fireside chat en el Cantor Global Healthcare Conference el 3 de septiembre, celebrará su 10-Year Anniversary R&D Day el 8 de septiembre con actualizaciones de datos clínicos y la participación del KOL Dr. Arun D. Singh, y asistirá al Morgan Stanley Global Healthcare Conference el 9 de septiembre para reuniones one-on-one.
El R&D Day mostrará varias actualizaciones de datos clínicos, señalará los próximos catalizadores y revisará la estrategia de cartera a largo plazo. Habrá webcasts de audio en directo en la web de relaciones con inversores de la compañía, con repeticiones disponibles durante 30 días tras el evento.
IDEAYA Biosciences (NASDAQ: IDYA), 정밀의학 기반 종양학 회사는 2025년 9월에 열리는 세 건의 주요 투자자 행사에 참여한다고 발표했습니다. 회사는 9월 3일 Cantor Global Healthcare Conference의 파이어사이드 챗에 참여하고, 9월 8일에는 임상 데이터 업데이트와 KOL Dr. Arun D. Singh를 초청한 10-Year Anniversary R&D Day를 개최하며, 9월 9일에는 Morgan Stanley Global Healthcare Conference에 참석해 일대일 미팅을 진행합니다.
R&D Day에서는 다수의 임상 데이터 업데이트를 공개하고 향후 주요 이벤트(촉매)를 제시하며 장기 포트폴리오 전략을 검토할 예정입니다. 회사의 투자자관계 웹사이트에서 라이브 오디오 웹캐스트를 시청할 수 있으며, 행사 종료 후 30일간 재생을 제공할 예정입니다.
IDEAYA Biosciences (NASDAQ: IDYA), société de médecine de précision en oncologie, a annoncé sa participation à trois grands événements investisseurs en septembre 2025. La société prendra part à un fireside chat au Cantor Global Healthcare Conference le 3 septembre, organisera son 10-Year Anniversary R&D Day le 8 septembre avec des mises à jour de données cliniques et l'intervention du KOL Dr. Arun D. Singh, et assistera au Morgan Stanley Global Healthcare Conference le 9 septembre pour des réunions individuelles.
Le R&D Day présentera plusieurs mises à jour de données cliniques, exposera les prochains catalyseurs et passera en revue la stratégie de portefeuille à long terme. Des webcasts audio en direct seront disponibles sur le site relations investisseurs de la société, avec des replays accessibles pendant 30 jours après l'événement.
IDEAYA Biosciences (NASDAQ: IDYA), ein Unternehmen für präzisionsmedizinische Onkologie, hat seine Teilnahme an drei wichtigen Investorenveranstaltungen im September 2025 angekündigt. Das Unternehmen wird am 3. September an einem Fireside Chat auf der Cantor Global Healthcare Conference teilnehmen, veranstaltet am 8. September den 10-Year Anniversary R&D Day mit klinischen Datenaktualisierungen und dem KOL Dr. Arun D. Singh, und nimmt am 9. September an der Morgan Stanley Global Healthcare Conference für Einzelgespräche teil.
Der R&D Day wird mehrere klinische Datenupdates vorstellen, zukünftige Meilensteine skizzieren und die langfristige Portfolio-Strategie überprüfen. Live-Audio-Webcasts sind auf der Investor-Relations-Website des Unternehmens verfügbar, Wiedergaben können 30 Tage nach der Veranstaltung abgerufen werden.
- None.
- None.
Cantor Global Healthcare Conference 2025
Wednesday, September 3rd, 2025 at 9:10 AM ET
- Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Li Watsek, Director, Biotechnology Analyst
IDEAYA Biosciences 10-Year Anniversary R&D Day
Monday, September 8th, 2025 at 8:00 AM ET
- The Company will host an in-person and virtual R&D Day to share multiple clinical data updates across the pipeline, outline upcoming catalysts and key growth drivers, and review its long-term portfolio strategy.
- The event will feature key opinion leader (KOL) Dr. Arun D. Singh, Director of the Department of Ophthalmic Oncology at the Cole Eye Institute, Cleveland Clinic, who will join members of the company's leadership team.
Morgan Stanley 23rd Annual Global Healthcare Conference
Tuesday, September 9th, 2025
- Management will be participating in one-on-one investor meetings.
A live audio webcast of the conference events, as permitted by the conference host, will be available at the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of available webcasts will be accessible for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-september-2025-investor-relations-events-302537011.html
SOURCE IDEAYA Biosciences, Inc.